Asset
SABIRNETUG
ACUMEN PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06511570 | phase1 | completed | 2024-06-25 | 2024-09-17 | Acumen Pharmaceuticals | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants |
| NCT06335173 | phase2 | active_not_recruiting | 2024-02-29 | 2026-10-01 | Acumen Pharmaceuticals | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) |
| NCT04931459 | phase1 | completed | 2021-06-21 | 2023-06-12 | Acumen Pharmaceuticals | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD |
FDA applications (0)
This company has no applications containing this asset.